GSK (NYSE: GSK) gains early FDA approval for ROS1 lung cancer therapy
Rhea-AI Filing Summary
GSK plc reports that the US Food and Drug Administration has approved Jideytro (zidesamtinib), a ROS1 selective kinase inhibitor, for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor. The decision comes ahead of the original target action date of 18 September 2026 and follows Breakthrough Therapy and Orphan Drug Designations.
The approval is based on the global single-arm ARROS-1 phase I/II trial in previously ROS1 inhibitor-treated patients, where among 117 patients the objective response rate was 44% and duration of response rates were 82% at six months and 69% at 12 months. A pooled safety population of 446 patients showed common adverse reactions including oedema, peripheral neuropathy, constipation, fatigue and dyspnoea.
Jideytro is GSK’s first approved lung cancer medicine and originates from the recently completed acquisition of Nuvalent, Inc. GSK also highlights additional targeted oncology programmes, including neladalkib (NVL-655) for ALK-altered NSCLC with a US FDA target decision date of 27 November 2026, NVL-330 for HER2-altered NSCLC, and the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) in late-stage development.
Positive
- FDA approval of Jideytro for previously treated ROS1-positive NSCLC, GSK’s first lung cancer medicine, validates the Nuvalent acquisition and expands the company’s targeted oncology portfolio.
Negative
- None.
Key Figures
Objective response rate: 44%
Duration of response at 6 months: 82%
Duration of response at 12 months: 69%
+4 more
7 metrics
Objective response rate
44%
Overall ARROS-1 population (n=117) with previously treated ROS1-positive NSCLC
Duration of response at 6 months
82%
Patients in ARROS-1 with ROS1-positive NSCLC previously treated with a ROS1 inhibitor
Duration of response at 12 months
69%
Same ARROS-1 efficacy population for Jideytro
ARROS-1 efficacy population
117 patients
Advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 inhibitor
Pooled safety population
446 patients
Used to characterise common adverse reactions to Jideytro
Annual ROS1-positive NSCLC diagnoses
50,000 people
Approximate worldwide yearly incidence of ROS1-positive NSCLC
Original FDA action date
18 September 2026
Initial target action date for the Jideytro US approval, met earlier than planned
Key Terms
Breakthrough Therapy, Orphan Drug Designations, objective response rate, duration of response, +1 more
5 terms
Breakthrough Therapy regulatory
"follows the FDA's Breakthrough Therapy and Orphan Drug Designations"
A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.
Orphan Drug Designations regulatory
"follows the FDA's Breakthrough Therapy and Orphan Drug Designations"
A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.
objective response rate medical
"In the overall population the objective response rate (ORR) was 44%"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
duration of response medical
"Duration of response (DOR) rates at six and 12 months were 82% and 69%"
Duration of response is the length of time a patient’s condition stays improved after a treatment until it starts to worsen again; think of it as how long a freshly charged battery continues to power a device. For investors, longer duration of response implies a treatment provides sustained benefit, which can boost a drug’s commercial value, support stronger regulatory labeling and payer coverage, and reduce the need for additional therapies.
antibody-drug conjugates medical
"accelerating priority programmes such as antibody-drug conjugates Ris-Rez targeting B7-H3"
A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did GSK (GSK) announce in this Form 6-K?
GSK announced that the US FDA approved Jideytro (zidesamtinib) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor, ahead of the original 18 September 2026 action date.
For which patients is Jideytro approved according to GSK (GSK)?
Jideytro is approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have received a prior ROS1 kinase inhibitor, targeting those whose disease has already been treated with another ROS1-directed therapy.
What key ARROS-1 trial results does GSK (GSK) report for Jideytro?
In the ARROS-1 phase I/II trial, among 117 previously ROS1 inhibitor-treated ROS1-positive NSCLC patients, Jideytro achieved a 44% objective response rate with duration of response rates of 82% at six months and 69% at 12 months.
What safety profile for Jideytro does GSK (GSK) describe?
In a pooled safety population of 446 patients, the most common adverse reactions (≥15%) with Jideytro were oedema, peripheral neuropathy, constipation, fatigue and dyspnoea, highlighting tolerability considerations alongside its clinical activity.
How does Jideytro fit into GSK (GSK)'s broader oncology strategy?
Jideytro is GSK’s first approved lung cancer medicine and part of a growing targeted portfolio that includes neladalkib (NVL-655) for ALK-altered NSCLC, NVL-330 for HER2-altered NSCLC, and the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan in late-stage development.
What other lung cancer programmes did GSK (GSK) highlight alongside Jideytro?
GSK highlighted neladalkib (NVL-655) for ALK-altered NSCLC, under FDA review with a target decision date of 27 November 2026, NVL-330 for HER2-altered NSCLC, and risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate in late-stage development.